Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan to Set Up Dedicated Team to Expedite Review of Sakigake-Designated Cell/Gene Therapies
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) will establish a team dedicated to reviewing cell and gene therapies designated for its sakigake fast-track pathway in FY2020 as it gears up for a flurry of approvals for these up-and-coming products. Funds…
To read the full story
Related Article
REGULATORY
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Japan’s Immunization Act Bill Set to Clear Diet after Session Extension
July 21, 2026
- Japan Eyes Early FY2027 Rollout of RSV Antibodies under NIP: Minister
July 21, 2026
- AMED-Backed R&D Yielded 31 Regulatory Approvals in FY2025
July 17, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…